Secukinumab biosimilar - Celltrion
Alternative Names: CT-P55; Secukinumab biosimilarLatest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Celltrion
- Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Plaque psoriasis
Most Recent Events
- 16 Oct 2024 Celltrion plans a phase III trial for Plaque psoriasis (SC, Injection) in April 2025 (NCT06630559) (EudraCT2024-513348-27)
- 08 Oct 2024 Preclinical trials in Plaque psoriasis in South Korea (SC) before October 2024